Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”